Fluid Biopsy - Global Strategic Business Report

The global market for Fluid Biopsy was valued at US$11.4 Billion in 2025 and is projected to reach US$24.6 Billion by 2032, growing at a CAGR of 11.5% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Fluid Biopsy Market - Key Trends & Drivers Summarized

Why Is Fluid Biopsy Emerging as a Disruptive Force in Cancer Diagnostics?

Fluid biopsy - also known as liquid biopsy - is transforming cancer diagnostics and disease monitoring by offering a non-invasive alternative to traditional tissue biopsies. By analyzing tumor-derived components such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and microRNAs from biological fluids (mainly blood), fluid biopsy enables early cancer detection, real-time disease tracking, and therapeutic response assessment. Its ability to capture tumor heterogeneity without the need for surgical sampling is particularly valuable in metastatic and inaccessible tumor settings.

This approach is gaining prominence in oncology due to its potential for detecting minimal residual disease (MRD), identifying actionable mutations, and guiding personalized therapy decisions across various cancer types - particularly lung, breast, colorectal, and prostate cancers. Unlike tissue biopsies that may be limited by procedural risks and spatial constraints, fluid biopsy allows for repeatable sampling over the disease course. As precision medicine continues to evolve, fluid biopsy is becoming an essential tool for dynamic tumor profiling and treatment adjustment.

What Technological Innovations Are Expanding the Potential of Fluid Biopsies?

Technological advancements in molecular biology, genomic sequencing, and digital PCR have significantly expanded the accuracy and clinical utility of fluid biopsies. Next-generation sequencing (NGS) platforms can now detect low-frequency mutations in ctDNA with high sensitivity, enabling early identification of tumor-related genomic alterations. Droplet digital PCR (ddPCR) and BEAMing (Beads, Emulsion, Amplification, Magnetics) are being utilized for mutation quantification, allowing for longitudinal tracking of tumor burden and therapy response.

Microfluidics-based platforms and CTC enrichment technologies are improving the capture efficiency of rare cells and particles from blood samples. Simultaneously, AI-driven data interpretation tools are facilitating rapid analysis of complex molecular signatures, supporting real-time clinical decision-making. Advances in multiplexing and integration of biomarkers from multiple fluid types - including urine, cerebrospinal fluid, and saliva - are extending fluid biopsy’s applications beyond oncology into other domains such as prenatal screening, organ transplant monitoring, and infectious disease surveillance.

Which Clinical and Therapeutic Areas Are Accelerating Adoption of Fluid Biopsy?

Fluid biopsy is primarily utilized in oncology, where it supports early cancer screening, companion diagnostics, and resistance mutation detection. In non-small cell lung cancer (NSCLC), for example, fluid biopsy is routinely used to detect EGFR mutations and guide the use of targeted therapies. Breast and prostate cancers are also key areas where serial fluid biopsies help monitor hormone receptor status and metastatic progression without repeated imaging or surgery.

Beyond solid tumors, hematological malignancies are beginning to benefit from ctDNA-based minimal residual disease detection, particularly in leukemias and lymphomas. Clinical trials now commonly incorporate fluid biopsy endpoints to stratify patients, evaluate drug efficacy, and correlate molecular response with clinical outcomes. Meanwhile, its application in immuno-oncology is expanding as researchers use fluid biopsy to assess tumor mutational burden (TMB) and predict response to checkpoint inhibitors. The versatility and scalability of fluid biopsy are also enabling broader adoption in population screening initiatives and point-of-care diagnostic frameworks.

What Are the Main Drivers Supporting Growth in the Fluid Biopsy Market?

The growth in the fluid biopsy market is driven by several converging factors rooted in clinical utility, technological maturity, and healthcare system needs. A primary driver is the growing demand for non-invasive, patient-friendly diagnostic tools that reduce procedure-related complications and enable frequent disease monitoring. This aligns with global trends favoring personalized medicine, early intervention, and outcomes-based treatment models.

The increasing availability of advanced sequencing technologies at lower costs is making fluid biopsy more accessible to both clinicians and diagnostic laboratories. Rising cancer incidence worldwide, combined with the need for timely, molecular-level decision support, is accelerating clinical adoption. Regulatory approvals for liquid biopsy-based companion diagnostics and reimbursement support in key markets are further solidifying its role in standard oncology workflows. Additionally, robust investments in precision oncology research, biopharma collaborations, and startup innovation are fueling a dynamic and competitive ecosystem that continues to expand the frontiers of fluid biopsy applications. Collectively, these drivers position fluid biopsy as a transformative force in the future of disease detection and personalized treatment.

Report Scope

The report analyzes the Fluid Biopsy market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

• Segments: Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Other Indications); Type (Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA)
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Lung Cancer segment, which is expected to reach US$9.7 Billion by 2032 with a CAGR of a 13.3%. The Breast Cancer segment is also set to grow at 9.2% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $3.1 Billion in 2025, and China, forecasted to grow at an impressive 15.4% CAGR to reach $5.2 Billion by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Fluid Biopsy Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Fluid Biopsy Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Fluid Biopsy Market expected to evolve by 2032?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2032?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Angle plc, Biocept, Inc., Bio-Rad Laboratories, Inc., Caris Life Sciences, CellMax Life and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Fluid Biopsy market report include:

• Angle plc
• Biocept, Inc.
• Bio-Rad Laboratories, Inc.
• Caris Life Sciences
• CellMax Life
• Cynvenio Biosystems, Inc.
• Epigenomics AG
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd
• Freenome Holdings, Inc.
• GRAIL, Inc.
• Guardant Health, Inc.
• Helio Health
• Illumina, Inc.
• Inivata Ltd
• Invitae Corporation
• Lucence Diagnostics Pte Ltd
• Menarini Silicon Biosystems
• Myriad Genetics, Inc.
• Natera, Inc.
• NeoGenomics Laboratories
• QIAGEN N.V.
• Resolution Bioscience (Agilent)
• Sysmex Corporation
• Tempus Labs, Inc.
• Thermo Fisher Scientific Inc.

What Sets This Report Apart From Others?

• Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
• Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
• Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
• Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
• Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
• Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.